Evaluating Alternatives to Fetal Bovine Serum in the Development of Advanced Biomaterial-Based Tumor Models: Overcoming Challenges in Biofabrication
Abstract
1. Introduction
2. Materials and Methods
2.1. Hydrogel Fabrication and Cell Culture
2.2. Metabolic Activity
2.3. Statistical Analysis
3. Results and Discussion
3.1. Alternative Serum Sources Sustain Cell Metabolic Activity in Glioma Cells Within Three-Dimensional Culture Platforms
3.2. Cells Respond to the Adhesive Peptide Sequences of Vitronectin and Laminin
3.3. Refined Cell Culture Conditions in the Biofabrication of In Vitro Tumor Models
| Cancer | Applications | Method | Ref. |
|---|---|---|---|
| Cervical | Identify crucial cell–biomaterial interactions | Design of Experiments (DOE) | [37] |
| Osteosarcoma | Define significant ECM-inspired physical cues that influence cancer progression and therapeutic resistance | Design of Experiments (DOE) | [38] |
| Pancreatic | Identify patient-specific matrix compositions that enhance EMT-associated transcriptional programs | Design of Experiments (DOE) | [39] |
| Brain and Breast | Chemotherapeutic efficacy | Tissue-engineered model—multistep process | [40] |
| Breast | Drug screening | High-throughput 3D bioprinting | [41] |
| Gastric, colorectal, lung | Drug screening Label-free phenotypic analysis | In silico staining | [42] |
| Multiple | Drug screening Biomarker discovery Imaging | AI-driven patient-derived organoids (PDOs) | [43] |
| Colon, adenoma adenocarcinoma | Identification of genotype-dependent soluble factors | Epithelial organoids | [44] |
| Colon | Development of precisely formulated, cost-effective media for organoid technology | R-spondin 1 and Gremlin 1 expression/purification workflow | [45] |
| (Healthy) brain-mimetic ECM | Four-dimensional presentation of active growth factors | Two-photon patterning microfabrication | [46] |
4. Conclusions and Future Directions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Neves, E.R.; Harley, B.A.C.; Pedron, S. Microphysiological systems to study tumor-stroma interactions in brain cancer. Brain Res. Bull. 2021, 174, 220–229. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Neves, E.R.; Anand, A.; Mueller, J.; Remy, R.A.; Xu, H.; Selting, K.A.; Sarkaria, J.N.; Harley, B.A.C.; Pedron-Haba, S. Targeting Glioblastoma Tumor Hyaluronan to Enhance Therapeutic Interventions that Regulate Metabolic Cell Properties. Adv. Ther. 2024, 7, 2400041. [Google Scholar] [CrossRef] [Scilit]
- Smith, L.J.; Skirzynska, A.; Chin, A.A.; Arnold, A.E.; Kushida, M.; Dirks, P.B.; Shoichet, M.S. Engineered In Vitro Tumor Model Recapitulates Molecular Signatures of Invasion in Glioblastoma. ACS Mater. Au 2023, 3, 514–527. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kim, S.-Y.; van de Wetering, M.; Clevers, H.; Sanders, K. The future of tumor organoids in precision therapy. Trends Cancer 2025, 11, 665–675. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Johnson, M. Fetal bovine serum. Mater. Methods 2012, 2, 10.13070. [Google Scholar] [CrossRef] [Scilit]
- Chelladurai, K.S.; Christyraj, J.D.S.; Rajagopalan, K.; Yesudhason, B.V.; Venkatachalam, S.; Mohan, M.; Vasantha, N.C.; Christyraj, J.R.S.S. Alternative to FBS in animal cell culture—An overview and future perspective. Heliyon 2021, 7, e07686. [Google Scholar] [CrossRef] [Scilit]
- Piletz, J.E.; Drivon, J.; Eisenga, J.; Buck, W.; Yen, S.; McLin, M.; Meruvia, W.; Amaral, C.; Brue, K. Human Cells Grown With or Without Substitutes for Fetal Bovine Serum. Cell Med. 2018, 10, 2155179018755140. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ghassemi, S.; Martinez-Becerra, F.J.; Master, A.M.; Richman, S.A.; Heo, D.; Leferovich, J.; Tu, Y.; García-Cañaveras, J.C.; Ayari, A.; Lu, Y.; et al. Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media Design. Mol. Ther. Clin. Dev. 2020, 18, 595–606. [Google Scholar] [CrossRef] [Scilit]
- Meng, H.; Day, P.J.R. Exploring ethical, sustainable and effective foetal bovine serum alternatives for in vitro mammalian cell culture. Front. Toxicol. 2026, 8, 2026. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Oredsson, S.; Malakpour-Permlid, A.; Zhu, J.; Weber, T. Protocol for the use of Oredsson universal replacement medium for cell banking and routine culturing of monolayer and suspension cultures. STAR Protoc. 2025, 6, 2103781. [Google Scholar] [CrossRef] [Scilit]
- Malakpour-Permlid, A.; Rodriguez, M.M.; Zór, K.; Boisen, A.; Oredsson, S. Advancing humanized 3D tumor modeling using an open access xeno-free medium. Front. Toxicol. 2025, 7, 1529360. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lee, D.Y.; Lee, S.Y.; Yun, S.H.; Jeong, J.W.; Kim, J.H.; Kim, H.W.; Choi, J.S.; Kim, G.D.; Joo, S.T.; Choi, I.; et al. Review of the Current Research on Fetal Bovine Serum and the Development of Cultured Meat. Food Sci. Anim. Resour. 2022, 42, 775–799. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wu, X.; Su, J.; Wei, J.; Jiang, N.; Ge, X. Recent advances in three-dimensional stem cell culture systems and applications. Stem Cells Int. 2021, 2021, 9477332. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Weissman, S.A.; Anderson, N.G. Design of Experiments (DoE) and Process Optimization. A Review of Recent Publications. Org. Process Res. Dev. 2015, 19, 1605–1633. [Google Scholar] [CrossRef] [Scilit]
- Narayanan, H.; Hinckley, J.A.; Barry, R.; Dang, B.; Wolffe, L.A.; Atari, A.; Tseng, Y.-Y.; Love, J.C. Accelerating cell culture media development using Bayesian optimization-based iterative experimental design. Nat. Commun. 2025, 16, 6055. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- An Ethical and Affordable Alternative for Fetal Bovine Serum. Available online: www.getplenty.bio (accessed on 13 July 2026).
- Hines, M.R.; Goetz, J.E.; Gomez-Contreras, P.C.; Rodman, S.N.; Liman, S.; Femino, E.L.; Kluz, P.N.; Wagner, B.A.; Buettner, G.R.; Kelley, E.E.; et al. Extracellular biomolecular free radical formation during injury. Free Radic. Biol. Med. 2022, 188, 175–184. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Van der Valk, J.; Brunner, D.; De Smet, K.; Svenningsen, Å.F.; Honegger, P.; Knudsen, L.E.; Lindl, T.; Noraberg, J.; Price, A.; Scarino, M. Optimization of chemically defined cell culture media–replacing fetal bovine serum in mammalian in vitro methods. Toxicol. Vitr. 2010, 24, 1053–1063. [Google Scholar] [CrossRef] [Scilit]
- Shirahama, H.; Lee, B.H.; Tan, L.P.; Cho, N.-J. Precise Tuning of Facile One-Pot Gelatin Methacryloyl (GelMA) Synthesis. Sci. Rep. 2016, 6, 31036. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Reiber, H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin. Chim. Acta 2001, 310, 173–186. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Stringer, B.W.; De Silva, M.I.; Greenberg, Z.; Puerta, A.N.; Adams, R.; Milky, B.; Zabolocki, M.; van den Hurk, M.; Ebert, L.M.; Bishop, C.F.; et al. Human cerebrospinal fluid affects chemoradiotherapy sensitivities in tumor cells from patients with glioblastoma. Sci. Adv. 2023, 9, eadf1332. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Alsabeeh, N.; Chausse, B.; Kakimoto, P.A.; Kowaltowski, A.J.; Shirihai, O. Cell culture models of fatty acid overload: Problems and solutions. Biochim Biophys. Acta Mol. Cell Biol. Lipids 2018, 1863, 143–151. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Tüysüz, N.; Van Bloois, L.; Van Den Brink, S.; Begthel, H.; Verstegen, M.M.; Cruz, L.J.; Hui, L.; Van Der Laan, L.J.; De Jonge, J.; Vries, R. Lipid-mediated Wnt protein stabilization enables serum-free culture of human organ stem cells. Nat. Commun. 2017, 8, 14578. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ledur, P.F.; Onzi, G.R.; Zong, H.; Lenz, G. Culture conditions defining glioblastoma cells behavior: What is the impact for novel discoveries? Oncotarget 2017, 8, 69185–69197. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Xie, Y.; Bergström, T.; Jiang, Y.; Johansson, P.; Marinescu, V.D.; Lindberg, N.; Segerman, A.; Wicher, G.; Niklasson, M.; Baskaran, S. The human glioblastoma cell culture resource: Validated cell models representing all molecular subtypes. EBioMedicine 2015, 2, 1351–1363. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Pristyazhnyuk, I.E.; Stupak, E.V.; Stupak, V.V.; Menzorov, A.G. Primary glioma cell culture: From monolayer to organoids. Protoplasma 2026, 263, 357–372. [Google Scholar] [PubMed]
- Yu, Q.; Xiao, W.; Sun, S.; Sohrabi, A.; Liang, J.; Seidlits, S.K. Extracellular Matrix Proteins Confer Cell Adhesion-Mediated Drug Resistance Through Integrin αv in Glioblastoma Cells. Front. Cell Dev. Biol. 2021, 9, 2021. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Persson, C.U.; von Stedingk, K.; Bexell, D.; Merselius, M.; Braekeveldt, N.; Gisselsson, D.; Arsenian-Henriksson, M.; Påhlman, S.; Wigerup, C. Neuroblastoma patient-derived xenograft cells cultured in stem-cell promoting medium retain tumorigenic and metastatic capacities but differentiate in serum. Sci. Rep. 2017, 7, 10274. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Chen, M.H.; Lu, C.; Sun, J.; Chen, X.D.; Dai, J.X.; Cai, J.Y.; Chen, X.L. Diagnostic and prognostic value of serum vitronectin levels in human glioma. J. Neurol. Sci. 2016, 371, 54–59. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Alrefai, H.; Nassour-Caswell, L.C.; Kumar, M.; Lin, B.J.M.; Schanel, T.L.; Eustace, N.J.; Zhang, J.Q.; Stackhouse, C.T.; Mukherjee, N.; Hicks, P.H.; et al. A Novel Serum-Free Triculture Model of Glioblastoma, Astrocytes, and Macrophages. Int. J. Mol. Sci. 2025, 26, 9335. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Piazza, F.; Ravaglia, B.; Caporale, A.; Svetić, A.; Parisse, P.; Asaro, F.; Grassi, G.; Secco, L.; Sgarra, R.; Marsich, E.; et al. Elucidating the unexpected cell adhesive properties of agarose substrates. The effect of mechanics, fetal bovine serum and specific peptide sequences. Acta Biomater. 2024, 189, 286–297. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Miranti, C.K.; Brugge, J.S. Sensing the environment: A historical perspective on integrin signal transduction. Nat. Cell Biol. 2002, 4, E83–E90. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Slack, R.J.; Macdonald, S.J.F.; Roper, J.A.; Jenkins, R.G.; Hatley, R.J.D. Emerging therapeutic opportunities for integrin inhibitors. Nat. Rev. Drug Discov. 2022, 21, 60–78. [Google Scholar] [PubMed]
- Burnouf, T.; Strunk, D.; Koh, M.B.C.; Schallmoser, K. Human platelet lysate: Replacing fetal bovine serum as a gold standard for human cell propagation? Biomaterials 2016, 76, 371–387. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Al-Kharusi, G.; Dunne, N.J.; Little, S.; Levingstone, T.J. The Role of Machine Learning and Design of Experiments in the Advancement of Biomaterial and Tissue Engineering Research. Bioengineering 2022, 9, 561. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- LeSavage, B.L.; Suhar, R.A.; Broguiere, N.; Lutolf, M.P.; Heilshorn, S.C. Next-generation cancer organoids. Nat. Mater. 2022, 21, 143–159. [Google Scholar] [PubMed]
- Cadena, I.A.; Buchanan, M.R.; Harris, C.G.; Jenne, M.A.; Rochefort, W.E.; Nelson, D.; Fogg, K.C. Engineering high throughput screening platforms of cervical cancer. J. Biomed. Mater. Res. Part A 2023, 111, 747–764. [Google Scholar] [CrossRef] [Scilit]
- Midkhatov, K.; Taylor, G.; Stevens, L.; Amer, M.H. A design-of-experiments strategy for engineering 3D topographical features in osteosarcoma modelling. Mater. Today Bio 2025, 35, 102455. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Nadernezhad, A.; Kast, V.J.; Pette, D.; Baenke, F.; Stange, D.E.; Werner, C.; Loessner, D. Bottom-Up Programming of Cell States in Cancer Organoids with Defined Synthetic Adhesion Cues. Adv. Mater. 2026, 38, e17390. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Harris, A.R.; Yuan, J.X.; Munson, J.M. Assessing multiparametric drug response in tissue engineered tumor microenvironment models. Methods 2018, 134, 20–31. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Shukla, P.; Bera, A.K.; Ghosh, A.; Kiranmai, G.; Pati, F. Assessment and process optimization of high throughput biofabrication of immunocompetent breast cancer model for drug screening applications. Biofabrication 2024, 16, 035030. [Google Scholar] [CrossRef] [Scilit]
- Yuan, Y.C.; Xu, B.B.; McCormack, J.; Huang, X.H.; Ma, J.Z.; Marshall, T.; Sun, Y.C.; Singh, H.; Fanelli, A.; Kulkarni, G.; et al. Deep Learning-Powered Scalable Cancer Organ Chip for Cancer Precision Medicine. Adv. Sci. 2026, 13, e16660. [Google Scholar] [CrossRef] [Scilit]
- Heinzelmann, E.; Piraino, F. AI-Enhanced Patient-Derived Cancer Organoids: Integrating Machine Learning for Precision Oncology. Organoids 2025, 4, 30. [Google Scholar] [CrossRef] [Scilit]
- Sato, T.; Stange, D.E.; Ferrante, M.; Vries, R.G.; Van Es, J.H.; Van Den Brink, S.; Van Houdt, W.J.; Pronk, A.; Van Gorp, J.; Siersema, P.D. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 2011, 141, 1762–1772. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Urbischek, M.; Rannikmae, H.; Foets, T.; Ravn, K.; Hyvönen, M.; de la Roche, M. Organoid culture media formulated with growth factors of defined cellular activity. Sci. Rep. 2019, 9, 6193. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Broguiere, N.; Lüchtefeld, I.; Trachsel, L.; Mazunin, D.; Rizzo, R.; Bode, J.W.; Lutolf, M.P.; Zenobi-Wong, M. Morphogenesis guided by 3D patterning of growth factors in biological matrices. Adv. Mater. 2020, 32, 1908299. [Google Scholar] [CrossRef] [Scilit]


Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Quansah, E.; Rivera, I.; Pedrón-Haba, S. Evaluating Alternatives to Fetal Bovine Serum in the Development of Advanced Biomaterial-Based Tumor Models: Overcoming Challenges in Biofabrication. Bioengineering 2026, 13, 842. https://doi.org/10.3390/bioengineering13070842
Quansah E, Rivera I, Pedrón-Haba S. Evaluating Alternatives to Fetal Bovine Serum in the Development of Advanced Biomaterial-Based Tumor Models: Overcoming Challenges in Biofabrication. Bioengineering. 2026; 13(7):842. https://doi.org/10.3390/bioengineering13070842
Chicago/Turabian StyleQuansah, Elizabeth, Isabella Rivera, and Sara Pedrón-Haba. 2026. "Evaluating Alternatives to Fetal Bovine Serum in the Development of Advanced Biomaterial-Based Tumor Models: Overcoming Challenges in Biofabrication" Bioengineering 13, no. 7: 842. https://doi.org/10.3390/bioengineering13070842
APA StyleQuansah, E., Rivera, I., & Pedrón-Haba, S. (2026). Evaluating Alternatives to Fetal Bovine Serum in the Development of Advanced Biomaterial-Based Tumor Models: Overcoming Challenges in Biofabrication. Bioengineering, 13(7), 842. https://doi.org/10.3390/bioengineering13070842

